Bluejay Diagnostics raises $125,000 in private placement to insiders at $2.00/share

Bluejay Diagnostics, Inc.

Issued 62,500 shares of common stock at $2.00 per share to five insiders, including CEO Neil Dey and Chair Donald Chase.
Gross proceeds of $125,000; sale closed on March 17, 2026, under Section 4(a)(2)/Reg D exemption.
No registration rights were granted; shares are restricted securities.
Proceeds likely used for general working capital; no other material terms disclosed.
All purchasers represented as accredited investors.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Bluejay Diagnostics, Inc. entered into Agreement with the purchasers named therein valued at $125,000 (effective 2024-03-14).

Action: entry
Agreement: equity purchase
Counterparty: the purchasers named therein
Value: $125,000
Effective: 2024-03-14

Exact text from the filing

On March 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) entered into a securities purchase agreement (the “Agreement”)

View on SEC.gov

269 material agreements filed in the last 30 days. Browse all material agreements →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-029261

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.